0000882104-20-000187.txt : 20201120
0000882104-20-000187.hdr.sgml : 20201120
20201120202202
ACCESSION NUMBER: 0000882104-20-000187
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201118
FILED AS OF DATE: 20201120
DATE AS OF CHANGE: 20201120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bazaar Alan Lee
CENTRAL INDEX KEY: 0001296974
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19756
FILM NUMBER: 201334079
MAIL ADDRESS:
STREET 1: 9 BEDFORD ROAD
CITY: KATONAH
STATE: NY
ZIP: 10536
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PDL BIOPHARMA, INC.
CENTRAL INDEX KEY: 0000882104
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943023969
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
BUSINESS PHONE: 775-832-8500
MAIL ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE
DATE OF NAME CHANGE: 19930328
4
1
wf-form4_160592170507877.xml
FORM 4
X0306
4
2020-11-18
0
0000882104
PDL BIOPHARMA, INC.
PDLI
0001296974
Bazaar Alan Lee
932 SOUTHWOOD BLVD.
INCLINE VILLAGE
NV
89451
1
0
0
0
Common stock
2020-11-18
4
M
0
37080
1.71
A
70515
D
Common stock
2020-11-18
4
F
0
26642
2.38
D
43873
D
Common stock
2020-11-20
4
S
0
33435
2.4227
D
10438
D
Stock Option (right to buy)
1.71
2020-11-18
4
M
0
37080
1.71
D
2021-04-17
2030-04-17
Common stock
37080.0
0
D
On May 21, 2020, the Company completed the distribution to its stockholders of its shares of common stock in Evofem Biosciences, Inc., which resulted in a $0.58 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan. On October 1, 2020, the Company completed the distribution to its stockholders of its shares of common stock in LENSAR, Inc., which resulted in a $0.78 reduction to the exercise price of the stock option at such time pursuant to the Company's wind-down retention plan.
/s/ Nathan Kyrszak, Attorney-in-Fact for Alan Bazaar
2020-11-19